<DOC>
	<DOCNO>NCT00002106</DOCNO>
	<brief_summary>To evaluate effect ranitidine immunologic indicator asymptomatic HIV-1 infect patient CD4 count 400-700 cells/mm3 .</brief_summary>
	<brief_title>A Pilot Randomized , Double-Blind , Placebo-Controlled , Parallel Design , Multicenter Trial Evaluate Effect Ranitidine Immunologic Indicators Asymptomatic HIV-1 Infected Subjects With CD4 Cell Count Between 400-700 Cells/mm3</brief_title>
	<detailed_description>Patients randomize receive either ranitidine match placebo bid 16 week , follow-up every 4 week week 20 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<criteria>Inclusion Criteria Patients must : Asymptomatic HIV1 infection . CD4 count 400700 cells/mm3 . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Significant illness . Acute illness randomization . Hemodialysis . Prior Medication : Excluded : Antiretroviral use within 60 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1994</verification_date>
	<keyword>Ranitidine</keyword>
</DOC>